Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Lantern Pharma Inc is a biotechnology business based in the US. Lantern Pharma shares (LTRN) are listed on the NASDAQ and all prices are listed in US Dollars. Lantern Pharma employs 14 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $5.64 |
|---|---|
| 52-week range | $4.76 - $15.00 |
| 50-day moving average | $5.72 |
| 200-day moving average | $7.54 |
| Wall St. target price | $31.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.26 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.64 from 2022-07-06
| 1 week (2022-06-30) | -1.23% |
|---|---|
| 1 month (2022-06-07) | -1.05% |
| 3 months (2022-04-05) | -21.23% |
| 6 months (2022-01-03) | N/A |
| 1 year (2021-07-07) | -59.42% |
|---|---|
| 2 years (2020-07-07) | -56.88% |
| 3 years (2019-07-03) | N/A |
| 5 years (2017-07-03) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -11.77% |
| Return on equity TTM | -19.09% |
| Profit margin | 0% |
| Book value | $6.03 |
| Market capitalisation | $61.8 million |
TTM: trailing 12 months
We're not expecting Lantern Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Lantern Pharma's shares have ranged in value from as little as $4.76 up to $15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantern Pharma's is 1.5787. This would suggest that Lantern Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Lantern Pharma Inc. , a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.